These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 18455522)

  • 1. The economic impact of HPV vaccines: not just cervical cancer.
    Myers ER
    Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522
    [No Abstract]   [Full Text] [Related]  

  • 2. [Developments in HPV vaccination].
    de Melker H; Kenter G; van Rossum T; Conyn-van Spaendonck M
    Ned Tijdschr Geneeskd; 2012; 156(47):A5410. PubMed ID: 23171565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
    Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
    Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky.
    Prasad SR; Hill R
    J Ky Med Assoc; 2008 Jun; 106(6):271-6. PubMed ID: 18630037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of optimal control in assessing the most cost-effective implementation of a vaccination programme: HPV as a case study.
    Brown VL; Jane White KA
    Math Biosci; 2011 Jun; 231(2):126-34. PubMed ID: 21377481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policy debate over human papillomavirus vaccines.
    Richman S
    J Low Genit Tract Dis; 2009 Apr; 13(2):128. PubMed ID: 19387138
    [No Abstract]   [Full Text] [Related]  

  • 16. [Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools].
    Dillner J; Andrae B; Westermark B
    Lakartidningen; 2006 Nov 1-7; 103(44):3377-9. PubMed ID: 17152260
    [No Abstract]   [Full Text] [Related]  

  • 17. Global human papillomavirus vaccination: can it be cost-effective?
    Crosbie EJ
    BJOG; 2012 Jan; 119(2):125-8. PubMed ID: 22168760
    [No Abstract]   [Full Text] [Related]  

  • 18. Who should get the HPV vaccine? Usage expands amid debate.
    Peres J
    J Natl Cancer Inst; 2010 Jun; 102(12):838-40. PubMed ID: 20530765
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
    Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
    Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of implementing human papillomavirus (HPV) vaccination policy.
    Raffle AE
    BMJ; 2007 Aug; 335(7616):375-7. PubMed ID: 17717366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.